CDC42BPA

Across TCGA pan-cancer cohorts, CDC42BPA Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CDC42BPA data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher CDC42BPA Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDC42BPA expression acts as an unfavorable survival marker, although some lineages such as UCEC and BRCA show a favorable association.

KIRP, KIRC, and UCEC are the cancer types where CDC42BPA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.563	0.948	<.001	48	view →
KIRC	OS	Median	II,III,IV	0.054	0.806	<.001	44	view →
UCEC	DFS	Median	All	0.937	0.603	.004	22	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
BRCA	DFS	Median	IV	1.000	0.236	.026	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CDC42BPA–KIRP (OS)

Open the KIRP breakdown →